Evidence map›Paper›PMID 38115869›Full record

ArticleMetabolism open2023

Effectiveness of a hybrid technology enabled care model as measured by ICHOM standard set on established and managed type 2 diabetes already using medications: A RWE retrospective study.

Ihsan Almarzooqi, Hala Zakaria, Sofia Aleabova, Milena Caccelli, Cigdem Ozkan, Judith Skaf, Jestoni Bangayan, Dianne Catapang, Zeinab Jaafar, Ali Hashemi and 1 more

Abstract read
In one paragraph

Article in Metabolism open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ihsan AlmarzooqiGluCare Integrated Diabetes Center, 268 Al Wasl Road, Jumeirah 1, Dubai, United Arab Emirates.
Hala ZakariaGluCare Integrated Diabetes Center, 268 Al Wasl Road, Jumeirah 1, Dubai, United Arab Emirates.
Sofia AleabovaGluCare Integrated Diabetes Center, 268 Al Wasl Road, Jumeirah 1, Dubai, United Arab Emirates.
Milena CaccelliGluCare Integrated Diabetes Center, 268 Al Wasl Road, Jumeirah 1, Dubai, United Arab Emirates.
Cigdem OzkanGluCare Integrated Diabetes Center, 268 Al Wasl Road, Jumeirah 1, Dubai, United Arab Emirates.
Judith SkafGluCare Integrated Diabetes Center, 268 Al Wasl Road, Jumeirah 1, Dubai, United Arab Emirates.
Jestoni BangayanGluCare Integrated Diabetes Center, 268 Al Wasl Road, Jumeirah 1, Dubai, United Arab Emirates.
Dianne CatapangGluCare Integrated Diabetes Center, 268 Al Wasl Road, Jumeirah 1, Dubai, United Arab Emirates.
Zeinab JaafarGluCare Integrated Diabetes Center, 268 Al Wasl Road, Jumeirah 1, Dubai, United Arab Emirates.
Ali HashemiGluCare Integrated Diabetes Center, 268 Al Wasl Road, Jumeirah 1, Dubai, United Arab Emirates.
Yousef SaidGluCare Integrated Diabetes Center, 268 Al Wasl Road, Jumeirah 1, Dubai, United Arab Emirates.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: Diabetes is a pressing global health issue, demanding innovative strategies for improved treatment. However, traditional care often falls short of patient goals. To address this, digital health solutions, including smartphone apps and remote monitoring, have emerged as crucial in diabetes management. This study aims to assess a comprehensive intervention, combining remote continuous data monitoring (RCDM) with in-clinic care, for enhancing diabetes-related outcomes. Additionally, it seeks to evaluate the effectiveness of the digital RCDM component by comparing adherent and non-adherent patients. Methods: Conducted in the United Arab Emirates, a retrospective study involved 89 patients primarily on anti-diabetic medications. They were split into two groups based on adherence to RCDM. Over time, significant improvements were observed across various parameters. Results: Notably, patients exhibited weight loss (-4.0 ± 5.3, p < 0.001), reduced waist circumference (-4.74 ± 7.8, p < 0.001), lowered HbA1c levels (-1.00 ± 1.3, p < 0.001), decreased systolic BP (-3.1 ± 13.1, p = 0.035), and diminished diastolic BP (-3.4 ± 9.9, p = 0.002) annually. Furthermore, patients adhering to the GluCare model demonstrated substantial HbA1c reductions (-1.53 ± 1.5, p < 0.001), improved lipid profiles, notably decreased total Cholesterol (-16.6 ± 50.3, p = 0.034), and lowered LDL levels (-18.65 ± 42.6, p = 0.006). Conclusions: The intervention model effectively managed T2D patients through a comprehensive approach, yielding notable improvements in HbA1c levels and other outcomes within a year. The study underscores the limitations of traditional care and reliance simply on pharmacotherapy, and emphasizes the need for a hyper-personalized, and continuous approach for T2D management.

Indexed as

Continuous Glucose MonitoringData-driven personalized medicineDiabetesDigital HealthDigital TherapeuticsGluCareHbA1c ReductionICHOMRemote Continuous Data MonitoringVirtual monitoring

Identifiers

PMID38115869
PMCPMC10728563

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.